Tuning the Triazolotriazine Scaffold Toward Selective A 3 Adenosine Receptor Antagonists: From Molecular Recognition to Neuroprotection
ChemMedChem · 28.10.2026 · 21 (20)
DOI: 10.1002/cmdc.70528 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 18.10.2026. Verfasst von Veronika Kost und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy. Hauptthemen laut MEDLINE: Triazines, Receptor, Adenosine A3, Neuroprotective Agents, Adenosine A3 Receptor Antagonists. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A series of 2,5,7‐trisubstituted [1,2,4]triazolo[1,5‐ a ][1,3,5]triazines (TTs) was developed to identify selective A 3 AR antagonists. Guided by previous structure–activity relationship studies, the C2‐furyl substituent was replaced with phenyl or 4‐methoxyphenyl moieties to improve A 3 AR affinity and selectivity. C2 phenyl substitution, together with appropriate C5 and C7 amino substituents, critically modulates receptor recognition. In particular, benzylamino substitution at C5 markedly enhanced A 3 AR affinity, yielding compound 15 as the most potent antagonist of the series ( K i = 0.485 nM), whereas incorporation of a 4‐methoxyphenyl group at C2 substantially improved subtype selectivity, exemplified by compound 30 (>2800‐fold selective for A 3 AR). Molecular docking at the recently determined antagonist‐bound structure of the A 3 AR rationalized these trends and identified key structural determinants of A 3 AR preference. The biological relevance of A 3 AR blockade was investigated in rat hippocampal slices subjected to oxygen‐glucose deprivation. Compound 15 delayed anoxic depolarization and, when administered during ischemia, prevented its onset in most slices and promoted near‐complete recovery of synaptic transmission. These findings identify TT derivatives as promising and highly selective A 3 AR antagonists with potential neuroprotective applications in cerebral ischemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy.
- Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
- Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
- Rudolf-Virchow-Zentrum - Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany.
- Institut für Pharmakologie und Toxikologie, University of Würzburg, Würzburg, Germany.
ORCID-Profile: Federica Panozzi, Elisabetta Coppi, Simone Adorinni, Stefano Moro, Stephanie Federico, Giampiero Spalluto
Zitieren
APA
Kost, V., Prencipe, F., Panozzi, F., Salmaso, V., Kachler, S., Klotz, K. N., Coppi, E., Adorinni, S., Moro, S., Pugliese, A. M., Federico, S., Spalluto, G., & Da Ros, T. (2026). Tuning the Triazolotriazine Scaffold Toward Selective A 3 Adenosine Receptor Antagonists: From Molecular Recognition to Neuroprotection. ChemMedChem, 21(20). https://doi.org/10.1002/cmdc.70528
Vancouver
Kost V, Prencipe F, Panozzi F, Salmaso V, Kachler S, Klotz KN, et al. Tuning the Triazolotriazine Scaffold Toward Selective A 3 Adenosine Receptor Antagonists: From Molecular Recognition to Neuroprotection. ChemMedChem. 2026;21(20). doi:10.1002/cmdc.70528
BibTeX
@article{Kost2026,
author = {Kost, Veronika and Prencipe, Filippo and Panozzi, Federica and Salmaso, Veronica and Kachler, Sonja and Klotz, Karl-Norbert and Coppi, Elisabetta and Adorinni, Simone and Moro, Stefano and Pugliese, Anna Maria and Federico, Stephanie and Spalluto, Giampiero and Da Ros, Tatiana},
title = {Tuning the Triazolotriazine Scaffold Toward Selective A 3 Adenosine Receptor Antagonists: From Molecular Recognition to Neuroprotection},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {20},
doi = {10.1002/cmdc.70528}
}
EUVIMED